Drugs /

azd4547

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.

Clinical Trials

View Clinical Trials for azd4547

Azd4547 has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating azd4547, 1 is phase 1/phase 2 (0 open) and 3 are phase 2 (3 open).

FGFR1 Amplification, FGFR2 Amplification, and ER Positive are the most frequent biomarker inclusion criteria for azd4547 clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and adenocarcinoma of the gastroesophageal junction are the most common diseases being investigated in azd4547 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Azd4547
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Azd4547
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating azd4547 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
fgfr inhibitor azd4547
Drug Categories [2]:
FGFR1/2/3 inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
FGFR1, FGFR2, FGFR3
NCIT ID [1]:
C88272

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.